{"id":21549,"date":"2025-01-14T21:47:26","date_gmt":"2025-01-14T13:47:26","guid":{"rendered":"https:\/\/flcube.com\/?p=21549"},"modified":"2025-01-14T21:47:27","modified_gmt":"2025-01-14T13:47:27","slug":"bristol-myers-squibb-exercises-license-for-arsenalbios-ab-4000-series","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21549","title":{"rendered":"Bristol-Myers Squibb Exercises License for ArsenalBio’s AB-4000 Series"},"content":{"rendered":"\n

US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY<\/a>) has exercised its exclusive license option for the AB-4000 series. This program originated from a multi-year agreement between the two companies, which was initially established in December 2020, aimed at advancing next-generation T cell therapies for the treatment of solid tumors.<\/p>\n\n\n\n

Agreement Details and Collaboration<\/strong>
Under the terms of the agreement, ArsenalBio is responsible for discovering and developing preclinical candidates against multiple targets. Bristol-Myers Squibb (BMS) retains the option to obtain an exclusive worldwide license to further develop and commercialize these preclinical candidates. Following the exercise of this option, BMS will assume sole responsibility for the development and commercialization of the licensed candidates.<\/p>\n\n\n\n

Expansion of Strategic Collaboration<\/strong>
In January 2022, BMS exercised an option to initiate a new program, further expanding its strategic collaboration with ArsenalBio. This was followed by a limited co-exclusive commercial license agreement in July 2023, which granted BMS the use of ArsenalBio’s proprietary TME control technology. This technology is intended to potentially enhance the therapeutic effects of CAR-T therapies in a limited number of BMS\u2019s cell therapy products.<\/p>\n\n\n\n

AB-4000 Series: Innovation in Solid Tumor Treatment<\/strong>
The AB-4000 series, developed using ArsenalBio\u2019s proprietary synthetic biology toolkit, is specifically designed to treat solid tumors. This innovative approach represents a significant step forward in the development of cell therapies, leveraging advanced synthetic biology techniques to improve treatment outcomes for patients with solid tumors.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY)…<\/p>\n","protected":false},"author":1,"featured_media":21550,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3149,16,77,849],"class_list":["post-21549","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-arsenal-biosciences","tag-cancer","tag-cell-therapy","tag-nyse-bmy"],"yoast_head":"\nBristol-Myers Squibb Exercises License for ArsenalBio's AB-4000 Series - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY) has exercised its exclusive license option for the AB-4000 series. This program originated from a multi-year agreement between the two companies, which was initially established in December 2020, aimed at advancing next-generation T cell therapies for the treatment of solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21549\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bristol-Myers Squibb Exercises License for ArsenalBio's AB-4000 Series\" \/>\n<meta property=\"og:description\" content=\"US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY) has exercised its exclusive license option for the AB-4000 series. This program originated from a multi-year agreement between the two companies, which was initially established in December 2020, aimed at advancing next-generation T cell therapies for the treatment of solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21549\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-14T13:47:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-14T13:47:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1407-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"373\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21549#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21549\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bristol-Myers Squibb Exercises License for ArsenalBio’s AB-4000 Series\",\"datePublished\":\"2025-01-14T13:47:26+00:00\",\"dateModified\":\"2025-01-14T13:47:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21549\"},\"wordCount\":252,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21549#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1407-1.png\",\"keywords\":[\"Arsenal Biosciences\",\"Cancer\",\"Cell-therapy\",\"NYSE: BMY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21549#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21549\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21549\",\"name\":\"Bristol-Myers Squibb Exercises License for ArsenalBio's AB-4000 Series - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21549#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21549#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1407-1.png\",\"datePublished\":\"2025-01-14T13:47:26+00:00\",\"dateModified\":\"2025-01-14T13:47:27+00:00\",\"description\":\"US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY) has exercised its exclusive license option for the AB-4000 series. This program originated from a multi-year agreement between the two companies, which was initially established in December 2020, aimed at advancing next-generation T cell therapies for the treatment of solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21549#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21549\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21549#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1407-1.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1407-1.png\",\"width\":1080,\"height\":373,\"caption\":\"Bristol-Myers Squibb Exercises License for ArsenalBio's AB-4000 Series\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21549#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bristol-Myers Squibb Exercises License for ArsenalBio’s AB-4000 Series\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bristol-Myers Squibb Exercises License for ArsenalBio's AB-4000 Series - Insight, China's Pharmaceutical Industry","description":"US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY) has exercised its exclusive license option for the AB-4000 series. This program originated from a multi-year agreement between the two companies, which was initially established in December 2020, aimed at advancing next-generation T cell therapies for the treatment of solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21549","og_locale":"en_US","og_type":"article","og_title":"Bristol-Myers Squibb Exercises License for ArsenalBio's AB-4000 Series","og_description":"US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY) has exercised its exclusive license option for the AB-4000 series. This program originated from a multi-year agreement between the two companies, which was initially established in December 2020, aimed at advancing next-generation T cell therapies for the treatment of solid tumors.","og_url":"https:\/\/flcube.com\/?p=21549","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-14T13:47:26+00:00","article_modified_time":"2025-01-14T13:47:27+00:00","og_image":[{"width":1080,"height":373,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1407-1.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21549#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21549"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bristol-Myers Squibb Exercises License for ArsenalBio’s AB-4000 Series","datePublished":"2025-01-14T13:47:26+00:00","dateModified":"2025-01-14T13:47:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21549"},"wordCount":252,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21549#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1407-1.png","keywords":["Arsenal Biosciences","Cancer","Cell-therapy","NYSE: BMY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21549#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21549","url":"https:\/\/flcube.com\/?p=21549","name":"Bristol-Myers Squibb Exercises License for ArsenalBio's AB-4000 Series - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21549#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21549#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1407-1.png","datePublished":"2025-01-14T13:47:26+00:00","dateModified":"2025-01-14T13:47:27+00:00","description":"US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY) has exercised its exclusive license option for the AB-4000 series. This program originated from a multi-year agreement between the two companies, which was initially established in December 2020, aimed at advancing next-generation T cell therapies for the treatment of solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21549#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21549"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21549#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1407-1.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1407-1.png","width":1080,"height":373,"caption":"Bristol-Myers Squibb Exercises License for ArsenalBio's AB-4000 Series"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21549#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bristol-Myers Squibb Exercises License for ArsenalBio’s AB-4000 Series"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1407-1.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21549"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21549\/revisions"}],"predecessor-version":[{"id":21551,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21549\/revisions\/21551"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21550"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}